Novo Nordisk A/S's (NYSE: NVO) widely used weight-loss medication, Wegovy, will be priced at €301.91 ($338.35) for a four-week course of the highest dosage in Germany.
The drug will be launched in Europe's biggest pharmaceutical market by the end of this month.
Standard Chartered PLC (OTC: SCBFY) reportedly agreed to a deal with Access Bank in Nigeria to sell its subsidiaries in sub-Saharan Africa for an undisclosed amount.
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)
UnitedHealth Group Inc (NYSE: UNH) reported nearly $5.5 billion, up 8% Y/Y in Q2 profits as its health insurance plans and Optum medical provider businesses grew by "double-digit" percentages